OTCMKTS:DNPUF

Sumitomo Pharma (DNPUF) Stock Price, News & Analysis

Sumitomo Pharma logo
$11.91 0.00 (0.00%)
As of 11/13/2026

About Sumitomo Pharma Stock (OTCMKTS:DNPUF)

Advanced

Key Stats

Today's Range
$11.91
▼
$11.91
50-Day Range
$9.27
▼
$14.21
52-Week Range
$8.41
▼
$19.20
Volume
N/A
Average Volume
1,303 shs
Market Capitalization
N/A
P/E Ratio
0.20
Dividend Yield
120.63%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sumitomo Pharma Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacture and commercialization of prescription medicines. Its portfolio and development activities have focused on psychiatric and neurological disorders, oncology, gynecological health and other areas of significant unmet medical need. The company also conducts research in regenerative medicine and cell therapy.

The company has marketed medicines including Latuda (lurasidone), an antipsychotic used in the treatment of schizophrenia and bipolar depression, as well as products for conditions such as overactive bladder and other specialized therapeutic areas. Its products and research programs have supported operations in Japan and international markets, including the United States and other regions.

Sumitomo Pharma was formed in 2005 through the merger of Dainippon Pharmaceutical and Sumitomo Pharmaceuticals and was previously known as Sumitomo Dainippon Pharma. The company adopted the Sumitomo Pharma name in 2022. It is headquartered in Osaka, Japan, and operates as part of the broader Sumitomo group of companies.

AI Generated. May Contain Errors.

Sumitomo Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
4th Percentile Overall Score

DNPUF MarketRank™: 
0.19541149793 of 5 stars

Sumitomo Pharma scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Sumitomo Pharma.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sumitomo Pharma is 0.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.37.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sumitomo Pharma is 0.20, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.

  • Read more about Sumitomo Pharma's valuation and earnings.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Sumitomo Pharma has a short interest ratio ("days to cover") of 78.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Sumitomo Pharma has recently increased by 50.49%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Sumitomo Pharma pays a meaningful dividend of 1.27%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Sumitomo Pharma does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Sumitomo Pharma is 24.70%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Sumitomo Pharma's dividend.
  • News Sentiment

    Sumitomo Pharma has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Sumitomo Pharma this week, compared to 0 articles on an average week.
Receive DNPUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sumitomo Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DNPUF Stock News Headlines

Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
See More Headlines

DNPUF Stock Analysis - Frequently Asked Questions

Sumitomo Pharma's stock was trading at $14.36 at the beginning of 2026. Since then, DNPUF stock has decreased by 17.0% and is now trading at $11.9135.

Shares of DNPUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
11/16/2026
Next Earnings (Estimated)
1/29/2027

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:DNPUF
CIK
N/A
Fax
N/A
Employees
3,123
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
0.20
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (OTCMKTS:DNPUF) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners